The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMycelx Di Regulatory News (MYX)

Share Price Information for Mycelx Di (MYX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 55.50
Bid: 53.00
Ask: 58.00
Change: 0.00 (0.00%)
Spread: 5.00 (9.434%)
Open: 55.50
High: 55.50
Low: 55.50
Prev. Close: 55.50
MYX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Business Update

24 Apr 2024 07:00

RNS Number : 7639L
MyCelx Technologies Corporation
24 April 2024
 

24 April 2024

 

MYCELX TECHNOLOGIES CORPORATION (AIM : MYX)

 

Business Update

 

MYCELX Technologies Corporation ("MYCELX" or the "Company"), the clean water and clean air technology company transforming the environmental impact of industry, is pleased to provide and update on its recent business development.

 

Following the successful completion of the sale of its Saudi Arabian business operations in Q1, the Company has focused its internal resources on accelerating its marketing and sales plan for its unique technologies in the Perfluoroalkyl and Polyfluoroalkyl Substances ("PFAS") remediation and Enhanced Oil Recovery ("EOR") markets. The initial result of this renewed strategy is starting to materialise and accordingly the Company is pleased to provide the following update on these two sectors:

 

PFAS Remediation

 

UNITED STATES

PILOT TRIALS

· Successful completion of treatability study paving the way for inclusion in a multiple technology, four-month pilot trial treating PFAS contamination at a municipal wastewater treatment facility. The trial is expected to commence in Q1 2025, and the final outcome of the trial is expected to determine the award of a lucrative contract by the municipality in 2025.

· Successfully running a short-term, emergency PFAS remediation project treating Aqueous Film Forming Foam ("AFFF") contaminated water at a refinery. Contracted by a global engineering company, MYCELX intends to leverage this success to win more AFFF clean-up projects from the engineering consultant and become their "go-to" solution for AFFF remediation worldwide.

· Ongoing pre-treatment system identification process for a landfill leachate project started in 2024. Currently in discussions with technology partner for pre-treatment equipment to prevent fouling of the MYCELX PFAS system and media.

· Ramped up Rapid Small Scale Column Tests at the Company's Texas facility to perform PFAS water characterisation and removal tests, with the aim of shortening pilot approval and sales cycles.

 

COMMERCIAL and STRATEGIC

· Expect to finalise an agreement with an established Point of Entry/Point of Use commercial and residential water system supplier in the US to integrate the Company's PFAS media into their product line. The recent US Geological Survey report states at least 45% of the nation's tap water is impacted by PFAS contamination. 

· Ongoing discussions with several large, potential partners in each of our PFAS target markets where the parties believe strategically integrating MYCELX's technology creates value for both companies.

 

CORPORATE

· Hired a technical expert with nine years of PFAS experience within a global water treatment and equipment company.

 

AUSTRALIA

· MYCELX is reporting a material uptick in media sales for PFAS systems leased or sold by its Australian distribution partner.

· MYCELX's distribution partner has had recent success in sales of systems.

for PFAS remediation at a liquid waste facility; and

through working with a global engineering firm, sales to three companies to remediate PFAS contaminated water.

 

 

REGEN for EOR and Beneficial Reuse

 

PILOT TRIALS

Middle East

· Currently running a pilot with a global energy technology company to showcase REGEN media's superior capabilities over nutshell media to other EOR producers. We expect to get more traction in the region with EOR producers with whom we have several active proposals.

Canada

· REGEN pilot trial commencing in May with Canadian EOR producer, which, if successful, could potentially result in c.a. $2 million project award.

 

COMMERCIAL and STRATEGIC

· Delivered first REGEN retrofit package contracted in 2023, which will enable our EOR customer in the Middle East to change from traditional nutshell media to REGEN media. We expect more projects with this producer as they retrofit and upgrade equipment and expand production.

· Received notification from a global product supplier to the EOR market that their testing concluded REGEN was the best technology for treatment of EOR produced water and they intend to bid their projects to include REGEN going forward with one bid already submitted.

 

CORPORATE

· Hired an experienced engineer to further strengthen the REGEN team with project start-up and commissioning experience, project proposal production and technical laboratory testing.

 

 

 

Connie Mixon, CEO, commented:

 

"We continue to be upbeat about the progress we have made in 2024 and the outlined developments mentioned reinforce the significant advancements we are making as a business. We intend to capitalise on positive recent developments in the US, following the publishing of the EPA PFAS Drinking Water regulations, and we continue to aggressively pursue partnerships, pilots, data collection and projects in our core markets. There is tremendous opportunity in the EOR market for our REGEN product. We are engaged with multiple producers who require better performance and a reliable solution to water management during production for EOR and beneficial reuse. Both our PFAS and REGEN offerings are designed to be best in class in their applications and we expect to see a continued uptick in demand for sales and/or pilot projects from globally recognisable firms over the rest of 2024."

 

For further information, please contact: 

 

MYCELX Technologies Corporation

Connie Mixon, CEO

Kim Slayton, CFO

 

 

 

Tel: +1 888 306 6843

Canaccord Genuity Limited (Nomad and Sole Broker)

Henry Fitzgerald-O'Connor

Ana Ercegovic

 

 

Tel: +44 20 7523 8000

Bellicourt Communications (Financial PR)

Mark Anselme

Jimmy Lea

Charlie Denley-Myerson

 

Tel: +44 20 7770 6424

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSEMFWDELSEEL
Date   Source Headline
24th Apr 20247:00 amRNSBusiness Update
11th Apr 20247:00 amRNSEPA Publishes National Drinking Water Standards
26th Mar 20243:30 pmRNSDirector Dealing
26th Mar 20247:00 amRNSDirector Dealing
22nd Mar 20247:00 amRNSDirector Dealing
21st Mar 20247:00 amRNSDirector Dealing
18th Mar 20247:00 amRNSGrant of Share Options to Chief Financial Officer
4th Mar 20247:00 amRNSSaudi Arabia Business Operation Sale Completion
22nd Feb 20247:02 amRNSTrading Update
22nd Feb 20247:00 amRNSSaudi Arabia Business Operation Sale
21st Nov 20237:00 amRNSContract Update
16th Nov 20237:00 amRNSTrading Update
26th Sep 20233:10 pmRNSResult of Annual Meeting
20th Sep 20237:00 amRNSHalf Year Results Statement
11th Jul 20237:00 amRNSContract Award
5th Jul 20233:28 pmRNSHolding(s) in Company
3rd Jul 20232:37 pmRNSContract Award & PFAS Update
21st Jun 20237:00 amRNSMailing of AR and Notice of 2023 Annual Meeting
18th May 20237:00 amRNSFinal Results for the Year Ending 31 December 2022
12th May 20237:00 amRNSHolding(s) in Company
17th Apr 20237:00 amRNSSuccessful leach testing of PFAS media
14th Mar 20234:50 pmRNSClosure of Restricted Stock Line
8th Mar 20237:00 amRNSPilot Testing Agreement for PFAS Remediation
13th Feb 20237:00 amRNSOperational Update
31st Jan 20237:00 amRNSTrading Update
24th Jan 20237:00 amRNSContract Secured for PFAS Remediation System
8th Dec 20227:00 amRNSTrading Update
27th Sep 20227:00 amRNSHalf Year Results Statement
15th Sep 20227:00 amRNSTrading Update
6th Sep 20222:30 pmRNSHolding(s) in Company
30th Aug 20227:00 amRNSNew Project Awards and Operations Update
13th Jul 20223:32 pmRNSResult of Annual Meeting
13th Jun 20227:00 amRNS2021 Annual Report & Notice of 2022 Annual Meeting
17th May 20227:00 amRNSFinal Results for Year Ending 31 December 2021
3rd May 20227:00 amRNSDirector/PDMR Shareholding
3rd May 20227:00 amRNSChange of Main Office Address
23rd Mar 20229:17 amRNSTR1
21st Mar 20225:56 pmRNSBroker Option
16th Mar 20224:09 pmRNSHolding(s) in Company
11th Mar 20221:10 pmRNSDealings by Directors
11th Mar 20227:00 amRNSProposed Placing and Subscription
11th Feb 20227:00 amRNSTrading Update
2nd Feb 202211:07 amRNSHolding(s) in Company
25th Jan 20227:00 amRNSSuccessful Trial of PFAS Remediation System
10th Jan 20227:00 amRNSAward of Green Economy Mark
23rd Nov 20212:36 pmRNSHolding(s) in Company
11th Nov 202111:51 amRNSDealings by Directors
9th Nov 20214:42 pmRNSDirector/PDMR Shareholding
5th Nov 20217:00 amRNSDirector/PDMR Shareholding
28th Oct 20214:34 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.